A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

NCT07492680 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: BMS-986504
DRUG: Daraxonrasib
DRUG: Nivolumab + Relatlimab FDC
DRUG: Temozolomide
DRUG: Pumitamig
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: Paclitaxel

Sponsor

Bristol-Myers Squibb